GlycoErase™ GALNT10 Knockout Human Lung Cancer Cell A-427 (CAT#: GLJF-0525-JF1308)

Description	The GALNT10 knockout A-427 cell line, deficient in polypeptide N-acetylgalactosaminyltransferase 10 involved in O-linked glycosylation and Notch signaling, can be used to dissect the role of O-glycosylation in lung adenocarcinoma Notch signaling, potentially impacting Notch-mediated cell fate decisions, tumor growth, and microenvironment interactions influenced by Notch.
Product Type	KO Cell Lines
Species	Human
Cell Morphology	Epithelial-like, adherent
Passage Ratio	1:2~1:3
Cell Line	A-427
Primary Disease	Non-Small Cell Lung Cancer
Lineage	Lung

Cell Viability	>90%
Sterility Test	The sterility test indicated an absence of microbial growth.
Identity Test	STR identification
Mycoplasma Test	Negative
Virus Test	Negative for HIV, HBV and HCV.
Genetic Stability Testing	We conduct cell genetic stability studies in full compliance with ICH guidelines. Our expertise enables us to design and execute a comprehensive testing program tailored to your specific needs and regulatory requirements.
Validation	PCR, Sanger Sequencing
Culture Medium	FBS & RPMI
Application	Functional assay
Size	1 M cells/vial*2
Product Format	Frozen
Shipping	Dry ice
Availability Status	Made to order
Handling Notes	Upon receipt, this product must be immediately transferred from dry ice to liquid nitrogen (-150°C to -190°C) and stored in a liquid nitrogen tank. Cell viability is critically dependent on proper handling. We cannot guarantee viability if these instructions are not strictly adhered to.
Product Disclaimer	This product is provided for research only, not suitable for human or animal use. Due to the inherent limitations of infectious agent testing, investigators must exercise extreme caution when handling cells provided by Creative Biolabs, treating all cells as potentially biohazardous.

Target	GALNT10
Full Name	Polypeptide N-acetylgalactosaminyltransferase 10
Alternative Name	GalNAc-T10
Location	5q33.2
Gene ID	55568
Summary	Catalyzes the first step in mucin-type oligosaccharide synthesis by transferring GalNAc from UDP-GalNAc to polypeptide acceptors.